From the Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, PA.
Hypertension. 2020 Oct;76(4):1308-1318. doi: 10.1161/HYPERTENSIONAHA.120.15822. Epub 2020 Aug 24.
Here, we tested the hypothesis that TNAP (tissue nonspecific alkaline phosphatase) modulates vascular responsiveness to norepinephrine. In the isolated, Tyrode's-perfused rat mesentery, 50 µmol/L of L-p-bromotetramisole (L-p-BT; selective TNAP inhibitor, K=56 µmol/L) significantly reduced TNAP activity and caused a significant 9.0-fold rightward-shift in the norepinephrine concentration versus vasoconstriction relationship. At 100 µmol/L, L-p-BT further reduced mesenteric TNAP activity and caused an additional significant right-shift of the norepinephrine concentration versus vasoconstriction relationship. A higher concentration (200 µmol/L) of L-p-BT had no further effect on either mesenteric TNAP activity or norepinephrine-induced vasoconstriction. L-p-BT did not alter vascular responses to vasopressin, thus ruling-out nonspecific suppression of vascular reactivity. Since in the rat mesenteric vasculature α-adrenoceptors mediate norepinephrine-induced vasoconstriction, these finding indicate that TNAP inhibition selectively interferes with α-adrenoceptor signaling. Additional experiments showed that the effects of TNAP inhibition on norepinephrine-induced vasoconstriction were not mediated by accumulation of pyrophosphate or ATP (TNAP substrates) nor by reduced adenosine levels (TNAP product). TNAP inhibition significantly reduced the Hillslope of the norepinephrine concentration versus vasoconstriction relationship from 1.8±0.2 (consistent with positive cooperativity of α-adrenoceptor signaling) to 1.0±0.1 (no cooperativity). Selective activation of A-adenosine receptors, which are known to participate in coincident signaling with α-adrenoceptors, reversed the suppressive effects of L-p-BT on norepinephrine-induced vasoconstriction. In vivo, L-p-BT administration achieved plasma levels of ≈60 µmol/L and inhibited mesenteric vascular responses to exogenous norepinephrine and sympathetic nerve stimulation. TNAP modulates vascular responses to norepinephrine likely by affecting positive cooperativity of α-adrenoceptor signaling via a mechanism involving A receptor signaling.
在这里,我们检验了假设,即 TNAP(组织非特异性碱性磷酸酶)调节去甲肾上腺素对血管的反应性。在分离的、用 Tyrode 液灌注的大鼠肠系膜中,50µmol/L 的 L-p-溴代四咪唑(L-p-BT;TNAP 的选择性抑制剂,K=56µmol/L)显著降低了 TNAP 活性,并使去甲肾上腺素浓度与血管收缩关系产生了显著的 9 倍右移。在 100µmol/L 时,L-p-BT 进一步降低了肠系膜 TNAP 活性,并使去甲肾上腺素浓度与血管收缩关系的右移进一步增加。更高浓度(200µmol/L)的 L-p-BT 对肠系膜 TNAP 活性或去甲肾上腺素引起的血管收缩均无进一步影响。L-p-BT 不改变血管对血管加压素的反应,从而排除了对血管反应性的非特异性抑制。由于在大鼠肠系膜血管中,α-肾上腺素受体介导去甲肾上腺素引起的血管收缩,这些发现表明 TNAP 抑制选择性地干扰了 α-肾上腺素受体信号传递。进一步的实验表明,TNAP 抑制对去甲肾上腺素引起的血管收缩的影响不是通过焦磷酸或 ATP(TNAP 底物)的积累或腺苷水平的降低(TNAP 产物)介导的。TNAP 抑制显著降低了去甲肾上腺素浓度与血管收缩关系的坡度,从 1.8±0.2(与 α-肾上腺素受体信号的正协同一致)降至 1.0±0.1(无协同)。A-腺苷受体的选择性激活,已知其参与与 α-肾上腺素受体的同时信号传递,逆转了 L-p-BT 对去甲肾上腺素引起的血管收缩的抑制作用。在体内,L-p-BT 给药达到约 60µmol/L 的血浆水平,并抑制了肠系膜血管对外源性去甲肾上腺素和交感神经刺激的反应。TNAP 可能通过一种涉及 A 受体信号的机制,通过影响 α-肾上腺素受体信号的正协同作用来调节去甲肾上腺素对血管的反应性。